Keeping science on top in drug evaluation

New England Journal of Medicine

Volumn 357, Issue 7, 2007, Pages 633-635

  Avorn, Jerry ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DEXFENFLURAMINE; ETORICOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; RIMONABANT; ROFECOXIB; ROSIGLITAZONE; TROGLITAZONE;

ANXIETY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFLICT OF INTEREST; CONGESTIVE HEART FAILURE; DECISION MAKING; DEPRESSION; DRUG APPROVAL; DRUG FATALITY; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; INSOMNIA; LIVER NECROSIS; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCIENCE; SHORT SURVEY; SIDE EFFECT; SUICIDAL BEHAVIOR; UNITED STATES; VALVULAR HEART DISEASE;

EID: 34547958547     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp078134     Document Type: Article

References (5)

1. Harris G, Berenson A. 10 Voters on panel backing pain pills had industry ties. New York Times. February 25, 2005:A1.
2. Wood S. Reauthorizing the Prescription Drug User Fee Act: how are PDUFA, the FDA budget, and drug safety related? Washington, DC: George Washington University School of Public Health and Health Services, April 2007. (Accessed July 26, 2007, at http://www.gwumc.edu/sphhs/about/rapidresponse/download/ RapidResponse_PDUFA.pdf.)
3. FDA Arthritis Advisory Committee. Arcoxia (etoricoxib). Rockville, MD: Food and Drug Administration, April 12, 2007. (Accessed July 26, 2007, at http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007-4290t1-Part4.pdf.)
4. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Alfred A. Knopf, 2005.
5. Center for Drug Evaluation and Research. NDA 21-888, Zimulti (rimonabant). Rockville, MD: Food and Drug Administration, June 13, 2007. (Accessed July 26, 2007, at http://www.fda.gov/ohrms/dockets/ac/07/transcripts/ 2007-4306t1-Part1.pdf.)